Our data demonstrate that vvDD-IL-23 treatment can deliver IL-23, not IL-23A to the tumor bed and elevate IL-10 expression and, in turn, prolong viral persistence and IL-23 accumulation. This evidence concerns the gene IL37 and neoplasm.